World J Urol:miR-3195、miR-3687和miR-4417的上调与去势抵抗性前列腺癌相关

2021-05-27 AlexYang MedSci原创

前列腺癌是男性生殖系统最常见的恶性肿瘤,其发病率和死亡率在欧美国家仅次于肺癌,位居男性癌症死亡的第2位。2014年,仅美国即新增前列腺癌患者233000人,死亡29480人,而2016年北美地区前列腺

前列腺癌是男性生殖系统最常见的恶性肿瘤,其发病率和死亡率在欧美国家仅次于肺癌,位居男性癌症死亡的第2位。2014年,仅美国即新增前列腺癌患者233000人,死亡29480人,而2016年北美地区前列腺癌预测新发病例约180890,占所有男性新发实体肿瘤总数的21%,且据预测,2023年前列腺癌治疗市场规模将增长至83亿美元。目前,尽管我国前列腺癌的发病率明显低于欧美,但是近10年来,由于社会老龄化、人口城市化、膳食结构西方化及血清前列腺特异性抗原(PSA)筛查的逐步推广,其发病率快速增长,正日益成为严重威胁我国男性健康的疾病。

前列腺癌(PCa)是癌症相关死亡的一个主要原因。雄激素阻断治疗后,该疾病可能进一步发展为去势抗性PCa(CRPC),且预后不佳。微核糖核酸(miRNAs)是一类小的非编码RNAs,在基因调控中发挥着关键作用。

近期,有研究人员分析鉴定了与CRPC相关的miRNAs,并评估了它们的功能作用

在这项研究中,共包括了23个良性前列腺增生症(BPH)样本、76个原发性PCa样本和35个CRPC样本。研究人员从组织切片中提取总RNA,并在Affymetrix GSC 3000平台上进行miRNA谱分析。随后,进行茎环结构RT-qPCR分析验证所选miRNA的表达水平。之后,研究人员使用用miRNA类似物或抑制剂转染PCa细胞系,评估其对细胞增殖、细胞迁移和细胞侵袭的影响。

在分析研究中,他们发现与原发性PCa组织相比,CRPC中的几个miRNAs表达失调,其中miR-205(-4.5倍;p=0.0009)、miR-92b(-3. 1倍;p<0.0001)下调;miR-3195(+5.6倍;p<0.0001)、miR-3687(+8.7倍;p=0.0006)和miR-4417(+5.0倍;p=0.0005)上调。虽然KLK3、miR-21和miR-141在雄激素处理的VCaP和LNCaP细胞中的表达水平有所增加,但miR-3687和miR-4417的表达水平却有所下降。在AR阴性的PC3细胞系中,没有一个miRNA是受雄性激素调控的。miR-3687的过量表达减少了细胞迁移和细胞侵袭,而miR-3195的过量表达增强了细胞迁移。

miR-205、miR-3195、miR-3687和miR-4417的表达以及与CRPC的相关性

综上所述,他们在CRPC组织中发现了几个新的失调的miRNAs,包括了两个可能参与肿瘤侵袭的miRNAs。他们的数据支持了miRNAs参与PCa肿瘤发生和发展为CRPC过程的假设。但miRNAs作为CRPC的新型生物标志物的适用性还有待进一步研究。

原始出处:

C G H Rönnau , S Fussek , F P Smit et al. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer. World J Urol. May 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930826, encodeId=a106193082651, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Dec 10 08:27:11 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048359, encodeId=bc60204835920, content=<a href='/topic/show?id=096a11881c8' target=_blank style='color:#2F92EE;'>#miR-31#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11881, encryptionId=096a11881c8, topicName=miR-31)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 01 10:27:11 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666079, encodeId=46a016660e952, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Apr 29 00:27:11 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342166, encodeId=d91113421660d, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 29 05:27:11 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041018, encodeId=f532104101884, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu May 27 17:27:11 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
    2021-12-10 一叶知秋
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930826, encodeId=a106193082651, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Dec 10 08:27:11 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048359, encodeId=bc60204835920, content=<a href='/topic/show?id=096a11881c8' target=_blank style='color:#2F92EE;'>#miR-31#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11881, encryptionId=096a11881c8, topicName=miR-31)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 01 10:27:11 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666079, encodeId=46a016660e952, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Apr 29 00:27:11 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342166, encodeId=d91113421660d, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 29 05:27:11 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041018, encodeId=f532104101884, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu May 27 17:27:11 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
    2021-09-01 redcrab
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930826, encodeId=a106193082651, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Dec 10 08:27:11 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048359, encodeId=bc60204835920, content=<a href='/topic/show?id=096a11881c8' target=_blank style='color:#2F92EE;'>#miR-31#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11881, encryptionId=096a11881c8, topicName=miR-31)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 01 10:27:11 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666079, encodeId=46a016660e952, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Apr 29 00:27:11 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342166, encodeId=d91113421660d, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 29 05:27:11 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041018, encodeId=f532104101884, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu May 27 17:27:11 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
    2022-04-29 yige2012
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930826, encodeId=a106193082651, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Dec 10 08:27:11 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048359, encodeId=bc60204835920, content=<a href='/topic/show?id=096a11881c8' target=_blank style='color:#2F92EE;'>#miR-31#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11881, encryptionId=096a11881c8, topicName=miR-31)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 01 10:27:11 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666079, encodeId=46a016660e952, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Apr 29 00:27:11 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342166, encodeId=d91113421660d, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 29 05:27:11 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041018, encodeId=f532104101884, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu May 27 17:27:11 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1930826, encodeId=a106193082651, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Dec 10 08:27:11 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048359, encodeId=bc60204835920, content=<a href='/topic/show?id=096a11881c8' target=_blank style='color:#2F92EE;'>#miR-31#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11881, encryptionId=096a11881c8, topicName=miR-31)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 01 10:27:11 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666079, encodeId=46a016660e952, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Apr 29 00:27:11 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342166, encodeId=d91113421660d, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 29 05:27:11 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041018, encodeId=f532104101884, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu May 27 17:27:11 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
    2021-05-27 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Nat Commun:“癌症之王”的新生物标志物?microRNA甲基化考虑一下

microRNA等与遗传功能相关的分子水平,可以作为与癌症相关的异常活动的重要指标。然而,对于癌细胞中不同的分子是如何改变的,我们知之甚少。现在,来自日本的研究人员发现了一种区分癌变组织和非癌变组织的新方法。

Gastroenterology:结肠癌患者粪便microRNA特征

粪便中2种miRNAs结合血红蛋白水平检测可更准确的鉴别高级腺瘤及结肠癌患者

Gastroenterology:粪便中MicroRNA谱可以检测大肠癌的发生

筛查结直肠癌(CRC)最广泛的办法就是粪便免疫化学测试,但是该方法受检测晚期腺瘤(AAs)的灵敏度低的限制。因此,本项研究旨在探究粪便样本中的microRNA(miRNA)是否可以鉴别A

JCC:MicroRNA23a在克罗恩病中的过度表达增加了抗TNF的敏感性并保护了上皮屏障

粘膜愈合在克罗恩病治疗中很重要。克罗恩病中肠上皮稳态失调,通透性增加,炎症和腹泻增加是显着的临床表现。MicroRNA是调节基因表达并在炎症性肠病中显示变化的小型非编码RNA。

Cell Death Dis:YY1/miR-548t-5p/CXCL11通路调节胰腺癌细胞的增殖和转移

胰腺导管腺癌(PDAC)是美国癌症死亡的第四大主要原因,其5年生存率仅约为9%。手术是治愈胰腺癌(PC)的唯一方法,然而只有5-20%的患者有机会接受手术,即便如此,经手术治疗的患者的中位生存期不超过

JNNP:C9orf72相关的额颞叶痴呆和肌萎缩侧索硬化症发病前和血浆microRNA特征

额颞叶性痴呆(FTD)是指中老年患者缓慢出现人格改变、言语障碍及行为异常的痴呆综合征。神经影像学显示额颞叶萎缩。本病是神经变性痴呆较常见的病因,约占全部痴呆病人的1/4。约1/4的额颞叶痴呆病人存在P